Chronic Administration of Lisdexamfetamine Induces Apoptosis and Inflammation and Reduces Sperm Quality in Adult Male Rats.
Susan RoustaeeMojtaba SaniMaryam MehranpourPourya RaeeMeysam Hassani MoghaddamReza BaharSeyedeh Naghmeh NouriradMohammad-Jasim GolzarianAmirreza BeiramiHosein JafaryMohammad Amin AalipourMohammad TaghizadehMohammad-Amin AbdollhifarKimia VakiliMobina FathiMohammad Hossain HeidariHojjat Allah AbbaszadehAbbas AghaeiHamid NazarianPublished in: Reproductive sciences (Thousand Oaks, Calif.) (2024)
Concerns have been raised about potentially irreversible brain damage and damage to the neuroendocrine system during development when treating attention-deficit/hyperactivity disorder with lisdexamfetamine (LDX), a norepinephrine dopamine reuptake inhibitor. This study aims to elucidate the potential adverse effects of LDX on the male reproductive system due to its widespread use and potential for abuse. In this study, adult male rats were randomized into control and LDX groups. Thirty milligrams per kilogram LDX was administered orally for 3 weeks. After isolation of epididymal spermatozoa, the rats were euthanized and testicular tissues were collected for stereological and molecular analyses. The LDX group showed a decrease in sperm motility and an increase in DNA fragmentation compared to the control group. There was also a dramatic decrease in testosterone in the LDX group. Testicular expression of caspase-3 and TNF-α was significantly increased in the LDX group. According to our findings, prolonged use of LDX leads to reduced sperm quality. It also induces apoptosis, inflammatory response, and pathological changes in the testicular tissue. What we have observed in this study is noteworthy but requires further investigation, particularly in people who use LDX over a longer period of time.
Keyphrases
- attention deficit hyperactivity disorder
- inflammatory response
- oxidative stress
- poor prognosis
- gene expression
- rheumatoid arthritis
- autism spectrum disorder
- emergency department
- clinical trial
- open label
- metabolic syndrome
- multiple sclerosis
- resting state
- functional connectivity
- blood brain barrier
- subarachnoid hemorrhage
- long non coding rna
- white matter
- brain injury
- phase iii
- placebo controlled
- prefrontal cortex
- endoplasmic reticulum stress